Natera, Inc. (NASDAQ:NTRA) Receives $120.07 Consensus Price Target from Brokerages

Natera, Inc. (NASDAQ:NTRA) has earned a consensus recommendation of “Buy” from the sixteen research firms that are covering the firm, MarketBeat Ratings reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $124.44.

Several research firms have weighed in on NTRA. TD Cowen boosted their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. The Goldman Sachs Group upped their price target on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird lifted their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Stephens reaffirmed an “overweight” rating and issued a $125.00 target price on shares of Natera in a report on Friday, August 9th. Finally, UBS Group reduced their price target on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 499 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total transaction of $53,592.60. Following the transaction, the chief financial officer now directly owns 77,418 shares of the company’s stock, valued at approximately $8,314,693.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Steven Leonard Chapman sold 2,638 shares of the company’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $105.16, for a total transaction of $277,412.08. Following the completion of the sale, the chief executive officer now directly owns 210,377 shares in the company, valued at approximately $22,123,245.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 499 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total value of $53,592.60. Following the sale, the chief financial officer now directly owns 77,418 shares in the company, valued at approximately $8,314,693.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,765 shares of company stock valued at $6,016,700. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after buying an additional 588,147 shares in the last quarter. Farallon Capital Management LLC raised its position in Natera by 13.6% during the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after purchasing an additional 532,874 shares in the last quarter. First Light Asset Management LLC lifted its stake in Natera by 295.9% during the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after purchasing an additional 490,822 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Natera by 257.6% in the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after purchasing an additional 469,327 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. bought a new position in shares of Natera in the 1st quarter valued at $33,938,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NTRA opened at $122.35 on Tuesday. The stock has a market capitalization of $15.02 billion, a price-to-earnings ratio of -39.21 and a beta of 1.53. Natera has a 12 month low of $36.90 and a 12 month high of $133.54. The firm has a fifty day simple moving average of $122.85 and a 200 day simple moving average of $110.07. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s quarterly revenue was up 58.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.97) EPS. Research analysts forecast that Natera will post -1.96 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.